QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TNGX

QT63Tango Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
27.97
-4.32-13.38%
OverviewShort InterestFilings
TNGXQT63Tango Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
27.97-13.38%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.91
Insider Own-
Shs Outstand-
Perf Week-6.20%
Market Cap4.02BForward P/E-EPS next Y-1.54Insider Trans-Shs Float-Perf Month37.78%
Enterprise Value3.89BPEG-EPS next Q-0.31Inst Own-Short Float-Perf Quarter44.77%
Income-92817196.00P/S70.50EPS this Y-44.78%Inst Trans-Short Ratio-Perf Half Y212.17%
Sales56.99MP/B11.84EPS next Y-16.89%ROA-24.61%Short Interest-Perf YTD215.69%
Book/sh-P/C-EPS next 5Y-ROE-41.54%52W High34.39 -18.67%Perf Year481.50%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-27.69%52W Low4.60 508.04%Perf 3Y-
Dividend Est.-EV/EBITDA-37.03Sales past 3/5Y35.36% 50.61%Gross Margin97.25%Volatility5.34% 10.50%Perf 5Y-
Dividend TTM-EV/Sales68.31EPS Y/Y TTM30.25%Oper. Margin-206.22%ATR (14)2.59Perf 10Y-
Dividend Ex-Date-Quick Ratio27.38Sales Y/Y TTM57.14%Profit Margin-188.15%RSI (14)54.14Recom2.25
Dividend Gr. 3/5Y-Current Ratio27.38EPS Q/Q11.11%SMA209.85%Beta1.22Target Price42.70
Payout0.00%Debt/Eq0.08Sales Q/Q-100.00%SMA5014.79%Rel Volume3.03Prev Close32.29
Employees155LT Debt/Eq0.09EarningsAug 04SMA20095.00%Avg Volume3.99MPrice27.97
IPO DateSep 03, 2020Option/ShortYes / YesEPS/Sales Surpr.-2.01% -Net Debt/EBITDA1.19Volume12,085,404Change-13.38%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26ReiteratedH.C. Wainwright$27 → $66
Jun-09-26ReiteratedCanaccord GenuityBuy$42
Jun-08-26ReiteratedMizuho Securities$30 → $36
Jun-08-26ReiteratedWolfe Research$35
Jun-08-26ReiteratedLeerink PartnersOutperform$69
May-15-26ReiteratedMizuho Securities$20 → $30
May-15-26DowngradePiper SandlerOverweight → Neutral$24
May-14-26ReiteratedUBS$28 → $55
May-14-26DowngradeJefferiesBuy → Hold$18 → $27
May-14-26ReiteratedWedbushOutperform$13 → $33
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue666242
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A120
Gross Profit666042
Selling, General and Administrative Excl. Other424244
Research and Development133132144
Other Operating Expense2-30
Operating Income-111-111-146
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-10-10-16
Net Income Before Taxes-101-102-130
Income Taxes
000
Consolidated Net Income-101-102-130
Net Income From Continuing Operations-101-102-130
Net Income-101-102-130
EPS (Recurring)-0.91-0.87-1.19
EPS (Basic, Before Extraordinaries)-0.91-0.87-1.19
EPS (Diluted)-0.91-0.87-1.19
EBITDA-98-99-128
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio47.0416.58—
Gross Margin100.0096.77100.00
Operating Margin-168.18-179.03-347.62
Net Margin-153.03-164.52-309.52
Shares Outstanding111116109
Market Capitalization3,1051,028—
Operating Lease Expense
———
Insider Trading Volume
$29.08$26.93$24.79$22.64$20.49● Close Price0.00M2.92M5.84M8.76M11.68MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Crystal AdamPresident, R&DJun 01 '26Option Exercise5.2054,000280,800341,040Jun 03 12:00 AM
Crystal AdamPresident, R&DJun 01 '26Sale22.8727,000617,571115,743Jun 03 12:00 AM
Crystal AdamPresident, R&DMay 01 '26Option Exercise5.2054,000280,800368,040May 05 12:00 AM
Crystal AdamPresident, R&DMay 01 '26Sale21.2327,000573,097115,743May 05 12:00 AM
Crystal AdamPresident, R&DApr 15 '26Option Exercise5.2076,920399,984395,040Apr 16 12:00 AM
Crystal AdamPresident, R&DApr 15 '26Sale25.0038,460961,500112,622Apr 16 12:00 AM
Crystal AdamPresident, R&DApr 01 '26Sale21.2027,000572,478112,622Apr 02 12:00 AM
Crystal AdamPresident, R&DApr 01 '26Option Exercise5.2054,000280,800433,500Apr 02 12:00 AM
Crystal AdamPresident, R&DMar 25 '26Sale20.1112,000241,320112,622Mar 27 12:00 AM
Crystal AdamPresident, R&DMar 25 '26Option Exercise5.2024,000124,800460,500Mar 27 12:00 AM
Crystal AdamPresident, R&DMar 05 '26Sale15.0020,251303,765112,622Mar 09 12:00 AM
Crystal AdamPresident, R&DFeb 25 '26Sale12.7754,345694,208132,873Feb 27 12:00 AM
Weber BarbaraDirector, Executive ChairFeb 03 '26Sale12.2630,519374,2941,629,254Feb 04 12:00 AM
Crystal AdamPresident, R&DFeb 03 '26Sale12.2618,452226,300187,218Feb 04 12:00 AM
Beckman DaniellaChief Financial OfficerFeb 03 '26Sale12.2610,317126,530184,297Feb 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR